A Massachusetts mother can proceed with a new legal claim against Amgen Inc. following her son's death after taking the company's migraine drug, Aimovig, in 2018. The First Circuit Court recently revived the lawsuit, allowing the plaintiff to pursue a revised theory of liability.
The case centers on the 2018 death of a 25-year-old man who had taken Aimovig, a medication approved by the FDA at the time. The plaintiff argues that Amgen failed to adequately warn about potential risks associated with the drug.
The First Circuit's ruling permits the mother to advance this claim, reversing a lower court's dismissal. The decision highlights the ongoing scrutiny over drug safety and labeling practices in the pharmaceutical industry.